- Home
- MESO vs NBXG Comparison
MESO vs NBXG Comparison
Compare MESO & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- NBXG
- Stock Information
- Founded
- MESO 2004
- NBXG 2021
- Country
- MESO Australia
- NBXG United States
- Employees
- MESO N/A
- NBXG N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- MESO Health Care
- NBXG Finance
- Exchange
- MESO Nasdaq
- NBXG Nasdaq
- Market Cap
- MESO 1.3B
- NBXG 1.1B
- IPO Year
- MESO N/A
- NBXG N/A
- Fundamental
- Price
- MESO $15.81
- NBXG $14.68
- Analyst Decision
- MESO Buy
- NBXG
- Analyst Count
- MESO 4
- NBXG 0
- Target Price
- MESO $18.00
- NBXG N/A
- AVG Volume (30 Days)
- MESO 148.6K
- NBXG 243.7K
- Earning Date
- MESO 09-02-2025
- NBXG 01-01-0001
- Dividend Yield
- MESO N/A
- NBXG 10.25%
- EPS Growth
- MESO N/A
- NBXG N/A
- EPS
- MESO N/A
- NBXG N/A
- Revenue
- MESO $5,670,000.00
- NBXG N/A
- Revenue This Year
- MESO $177.23
- NBXG N/A
- Revenue Next Year
- MESO $314.04
- NBXG N/A
- P/E Ratio
- MESO N/A
- NBXG N/A
- Revenue Growth
- MESO N/A
- NBXG N/A
- 52 Week Low
- MESO $6.00
- NBXG $9.31
- 52 Week High
- MESO $22.00
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- MESO 58.97
- NBXG 51.27
- Support Level
- MESO $14.68
- NBXG $14.39
- Resistance Level
- MESO $16.38
- NBXG $14.95
- Average True Range (ATR)
- MESO 0.44
- NBXG 0.18
- MACD
- MESO -0.14
- NBXG -0.05
- Stochastic Oscillator
- MESO 67.05
- NBXG 48.74
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".